Communiqués Sernova Corp. Toronto S.E.

Actions

SVA

CA81732W1041

Marché Fermé - Toronto S.E. Autres places de cotation 21:59:59 05/07/2024			Varia. 5j.	Varia. 1 janv.
0,33 ^CAD	-1,49 %		-1,49 %	-52,86 %

14/06	Sernova Corp. annonce ses résultats pour le deuxième trimestre et le semestre clos le 30 avril 2024	CI
28/05	Sernova Corp. nomme Jonathan Rigby au conseil d'administration	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Sernova Announces Additional Patient Insulin Independence and Cohort 2 Enrollment Completion in Ongoing Phase I/II Clinical Trial for Treatment of Type 1 Diabetes	26/06	AQ
Sernova Announces Additional Patient Insulin Independent and Cohort 2 Enrollment Complete in Ongoing Phase I/II Clinical Trial for Treatment of Type 1 Diabetes	25/06	AQ
Sernova : 2024 Q2 Financial Statements	17/06	PU
Sernova Announces Marketed Public Offering of Units	06/06	AQ
Sernova Appoints Jonathan Rigby to its Board of Directors	28/05	AQ
Sernova Announces AGM Voting Results	01/05	AQ
Sernova Provides Organizational Update	25/04	AQ
Sernova Welcomes Dr. Bernd Muehlenweg as Evotec's Nominee for its Board of Directors	22/04	AQ
Sernova Provides Positive Clinical and Platform Portfolio Update	03/04	AQ
Sernova : INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	19/03	PU
Sernova : Corporate Presentation March 2024	15/03	PU
Sernova Announces Management Developments	11/03	AQ
Sernova Provides Recap of 2023 Accomplishments and Anticipated 2024 Milestones	29/01	AQ
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA	27/11	AQ
Sernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System at the 2023 IPITA-IXA-CTRMS Joint Congress	31/10/23	AQ
Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress	30/10/23	AQ
Sernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress	30/10/23	AQ
Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress	27/10/23	AQ
Sernova to Provide Two Program Updates in Podium Presentations at 2023 IPITA Congress	11/10/23	AQ
Sernova Presents Compelling New Data on the Cell Pouch System as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual Meeting	02/10/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Sernova Corp. Toronto S.E.

Actions

SVA

CA81732W1041

Communiqués

Filtres